The NHS recently announced a £50 million fund to accelerate AI-based technologies for improving healthcare. Among the 42 funded recipients, Ibex Medical Analytics was the sole company chosen that offers AI tools for pathology.
Ibex’s AI-based tools for cancer diagnostics are the first, and to date only, in routine clinical use in pathology laboratories around the world. As part of the new initiative, Ibex’s Galen Prostate solution will initially be used to detect cancer and other clinically important features in prostate biopsies taken from hundreds of men across several NHS hospitals. The image shows p63 staining on prostate cancer tissue.
This comes as pandemic-related disruptions to UK cancer care have led to screening backlogs for a reported two million people. At the same time, screening tests for prostate cancer are expected to double from the current volume by 2030, while a reported 97% of NHS laboratories face a shortage of pathologists, leading to weeks-long delays for results, and increased concern over misdiagnosis.